Dear editor
Zhao et al have presented the result of the relative cardiovascular safety profile in using anastrozole, letrozole, and exemestane to treat the postmenopausal estrogen receptor-positive breast cancer, in which fatal or nonfatal myocardial infarction is the outcome measure and ten randomized controlled trials are used as the data sources.Citation1 We congratulate and applaud their important work, but there are some issues of concern.
First, the difference in duration of adjuvant tamoxifen therapy among the studies led to heterogeneity and inconsistency. For instance, the duration of tamoxifen therapy was 2 years in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial, whereas it was 5 years in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. In fact, the duration of tamoxifen therapy is relevant to toxicity. The practice of “lumping” cotreatments together generally makes no sense in clinical practice.Citation2 In addition, the author regarded the sequential therapy (tamoxifen for 2 years followed by anastrozole for 3 years) or the extended adjuvant therapy (tamoxifen for 5 years followed by anastrozole for 3 years) as the anastrozole group, which was misleading. In fact, the tamoxifen would have the “crossover” effect even after the completion of the 2-, 3-, or 5-year treatment period. Instead, the author should have considered comparing the safety prolife among the initial aromatase inhibitor therapy, sequential therapy, and extended therapy, which would be of a more meaningful clinical significance.
Second, the authors failed to include three relevant randomized controlled trials in their meta-analysis, although they apparently met their inclusion criteria.Citation3–Citation5
Third, there was one important methodological issue in this review. The reporting of the inconsistency between the direct and indirect comparison is laudable in a network meta-analysis. However, this review did not describe the methodology of the inconsistency analysis in the “Statistical analysis” section.
Finally, in Figure 3, it was described that both severe and total cardiovascular risk deviance information criterion values were <200, which means that the calculated results were convincible. We are interested in the source of this perspective. In addition, the methodology of model fit was not confirmed in the “Statistical analysis” section.
Disclosure
The authors report no conflicts of interest in this communication.
References
- ZhaoXLiuLLiKLiWZhaoLZouHComparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysisOnco Targets Ther201582721273026491345
- AdesAECaldwellDMRekenSWeltonNJSuttonAJDiasSEvidence synthesis for decision making 7: a reviewer’s checklistMed Decis Making201333567969123804511
- BonneterreJThurlimannBRobertsonJFAnastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability studyJ Clin Oncol200018223748375711078487
- NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol200018223758376711078488
- ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol200826304883489018794551